Alnylam announces pricing of offering of $900 million convertible senior notes

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (“alnylam”) (nasdaq: alny), the leading rnai therapeutics company, announced today the pricing of its previously announced private offering of $900 million aggregate principal amount of 1.00% convertible senior notes due 2027 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to rule 144a under the securities act of 1933, as amended (the “securities act”). in addition, alnylam granted the in
ALNY Ratings Summary
ALNY Quant Ranking